Navigation Links
NovaBay and Galderma Enter Into Global Agreement to Develop and Commercialize NovaBay's Novel Aganocide Drugs for Major Dermatological Conditions
Date:3/25/2009

- Up to $50 Million Potential Milestones plus Double Digit Royalties on Future Sales -

- Company to Host Conference Call at 11:00 a.m. ET Today -

EMERYVILLE, Calif., March 25 /PRNewswire-FirstCall/ -- NovaBay Pharmaceuticals, Inc. (NYSE Amex: NBY), a mid-stage biopharmaceutical company developing first-in-class anti-infective products for the treatment and prevention of a wide range of infections without causing resistance, today announced that it has entered into an agreement with Galderma S.A. to develop and commercialize NovaBay's novel proprietary Aganocide(R) compounds. The exclusive agreement is worldwide in scope, with the exception of certain Asian markets, and covers all major dermatological conditions, excluding onychomycosis (nail fungus) and orphan drug indications.

Under the terms of the agreement, NovaBay expects to receive from Galderma up to $50 million upon achievement of certain development and regulatory milestones related to the acne and impetigo indications and future royalties on net sales of products. The agreement also envisages further cooperation for additional dermatological products and indications. Under the agreement, NovaBay will also receive escalating double-digit royalties on net sales of products.

Galderma will be responsible for the development costs of the acne and other indications, except in Japan, and for the ongoing development program for impetigo, upon the achievement of a specified milestone. Galderma will also reimburse NovaBay for the use of its personnel in support of the collaboration. NovaBay retains the right to co-market products resulting from the agreement in Japan. In addition, NovaBay has retained all rights in other Asian markets outside Japan, and has exclusive rights to promote the products developed under the agreement in the hos
'/>"/>

SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. NovaBay Pharmaceuticals Prices Initial Public Offering of Common Stock
2. Galderma Completes Acquisition of CollaGenex
3. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
4. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
5. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
6. Center for Molecular Medicine Only Regional Provider of Test Suggested in FDA Alert on Prescribing Codeine to Nursing Mothers
7. Vital Images Releases Next Generation Enterprise-Wide Solutions Featuring Vitrea(R) 4.0 and ViTALConnect(R) 4.1
8. UniCare Unveils Community Resource Center in Topeka to Serve Medicaid Enrollees
9. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
10. Neogen Acquires Kane Enterprises
11. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... July 27, 2015 IDEXX Laboratories, Inc. (NASDAQ: ... clinics have submitted over 100,000 specimens to IDEXX Reference ... the first 10 days since the breakthrough kidney function ... is a leading cause of suffering and death in ... are consistent with generally accepted kidney disease prevalence data ...
(Date:7/26/2015)... ... July 26, 2015 , ... ... ANEMIA calibration verification / linearity test kit. The VALIDATE® ANEMIA kit contains Ferritin, ... kit is prepared using the CLSI recommended “equal delta” method for linearity testing ...
(Date:7/24/2015)... 2015 Ryan & Maniskas, LLP that ... District Court for the Northern District of California ... purchased the common stock of Avalanche Biotechnologies, Inc. ("Avalanche" or ... and June 15, 2015, inclusive (the "Class Period"). ... the Court for appointment as a lead plaintiff of the ...
(Date:7/24/2015)... NEW YORK , July 24, 2015 ... the following equities: PDL BioPharma Inc. (NASDAQ: PDLI ... Inc. (NASDAQ: STEM ), Northwest Biotherapeutics Inc. (NASDAQ: ... ACOR ). Free research report on PDL BioPharma can ... 23, 2015, the NASDAQ Composite ended at 5,146.41, down ...
Breaking Biology Technology:Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 2Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 3Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 4Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 5Maine Standards Company, LLC Announces Release of VALIDATE® ANEMIA Calibration Verification / Linearity Test Kit 2Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Avalanche Biotechnologies, Inc. 2Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Avalanche Biotechnologies, Inc. 3Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 2Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 3Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 4Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 5
... SPRINGFIELD, N.J., July 9 Adding to the ... reimbursement,actions are in motion by the American Medical ... proponents to eliminate commercial,support of certified CME. Certified ... new information is communicated to physicians so that ...
... ANN ARBOR, Mich., July 9 Terumo Cardiovascular ... patent infringement complaint in,Germany against two affiliates of ... Maquet Vertriebs und Service Deutschland GmbH. The complaint,alleges ... 7,Endoscopic Vessel Harvesting Systems, infringe a patent for ...
... after recent CE clearance Ovalum Ltd., a privately ... the launch of sales of its new CiTop™ ... vasculature. The devices are intended to assist ... (CTO). These obstructions are hard to traverse and ...
Cached Biology Technology:Terumo Cardiovascular Systems Files Patent Infringement Complaint Against Maquet Affiliates 2Ovalum Ltd. Announces Sales Launch of CiTop™ Product-Line in Europe 2
(Date:7/21/2015)... , July 21, 2015 Passwords have ... seen in the recent U.S. Office of Personnel ... to the infosec conundrum, but developers and end-users ... To address this dilemma, Biometrics-as-a-Service provider HYPR Corp. ... Tokenization SDK for third party integration. ...
(Date:7/13/2015)... Calif. , July 13, 2015 ... developer of human interface solutions, today announced sampling ... touch and display driver integration (TDDI) product targeting ... the first to combine Synaptics , best-in-class ... proven display driver technology developed in the company,s ...
(Date:7/9/2015)... SAN JOSE, Calif. , July 9, 2015 /PRNewswire/ ... human interface solutions, announced today that it will report ... 2015 on Thursday, July 30, 2015 after the close ... call for analysts and investors at 2:00 p.m. PT ... information.    To participate on the live ...
Breaking Biology News(10 mins):HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
... (VBI) at Virginia Tech have constructed a mathematical and ... to simulate the cellular and molecular changes underlying chronic ... to explore different interactions of cells in the immune ... in the colon, and identify intervention points to perhaps ...
... University of British Columbia zoologist has discovered a new ... and one of the earliest vertebrates dating back 500 ... evolution of steroid hormones and may help conservation and ... significant scientific implications and application for lamprey conservation," says ...
... WOODS HOLE, MAWhen searching for long-lost treasure, sometimes all ... "flashlight," developed at the Marine Biological Laboratory,s (MBL) Josephine ... long-neglected cellular component the nucleolinus and confirm ... and Mary Anne Alliegro, and MBL visiting investigator Jonathan ...
Cached Biology News:Math model of colon inflammation singles out dangerous immune cells 2Math model of colon inflammation singles out dangerous immune cells 3UBC researcher discovers ancient 'stress hormone' in pre-historic fish 2Rediscovery: MBL scientists confirm role for mysterious cell component, the nucleolinus 2
... ANTI-RNase is a protein ribonuclease inhibitor that noncovalently ... No inhibition is seen with RNase 1, T1, ... distinct from human placental ribonuclease inhibitor in that ... and does not release active RNase in the ...
... Ribonuclease Inhibitor is a recombinant protein that ... of RNA in the preparation of cDNA by ... in vitro protein synthesis. RNA Safe Inhibitor tightly ... a broad range of eukaryotic RNases such as ...
... Natural and Recombinant RNasin Ribonuclease Inhibitors ... the inhibition of eukaryotic RNases of the ... its inhibitory effect by noncovalently binding to ... value for the binding of RNasin Ribonuclease ...
...
Biology Products: